Human MMP-2(Matrix Metalloproteinase 2) ELISA Kit

MTDH is overexpressed in many malignant tumors and is closely related to the occurrence and development of tumors. The purpose of this study is to explore the effects of the knockdown of the MTDH gene on the proliferation and metastasis of human bladder cancer in T24 cells. shRNA plasmids targeting MTDH were constructed and transfected into T24 cells. The effects of gene silencing were confirmed by qPCR (Quantitative real-time PCR) and Western blotting. An MTT assay was used to determine the effects of MTDH on the proliferation of the T24 cells. The cell apoptosis rate was determined using Hoechst 33342. We additionally determined the expressions of caspase-3, JAK (Janus Activated Kinase) 1, P-JAK1, STAT (Signal transducers and activators of transcription) 3, P-STAT3, and MTDH using Western blotting, and the secretions of the tumor invasion-related proteins (MMP2 and MMP9) were determined using ELISA. The results showed that MTDH RNAI was constructed and transfected into the T24 cells successfully. Compared to the control groups, the MTDH, P-JAK1, and P-STAT3 proteins were reduced significantly, but the level of caspase-3 was clearly increased in the MTDH RNAI groups. Cell apoptosis was significantly increased in the MTDH RNAI groups. The secretions of MMP2 and MMP9 were decreased, and the cells' ability to proliferate and invade decreased significantly after MTDH RNAI was transfected into the T24 cells. In conclusion, we constructed an shRNA plasmid targeting MTDH, and it was successfully transfected into T24 cells. The knockdown of MTDH expression may inhibit proliferation and invasion via the JAK1/STAT3 pathway in T24 cells. Therefore, MTDH may be a new target for the genetic treatment of human bladder cancer.

The overall survival of patients with lower grade glioma (LGG) varies greatly, but the current histopathological classification has limitations in predicting patients' prognosis. Therefore, this study aims to find potential therapeutic target genes and establish a gene signature for predicting the prognosis of LGG. CD44 is a marker of tumor stem cells and has prognostic value in various tumors, but its role in LGG is unclear. By analyzing three glioma datasets from Gene Expression Omnibus (GEO) database, CD44 was upregulated in LGG. We screened 10 CD44-related genes via protein-protein interaction (PPI) network; function enrichment analysis demonstrated that these genes were associated with biological processes and signaling pathways of the tumor; survival analysis showed that four genes (CD44, HYAL2, SPP1, MMP2) were associated with the overall survival (OS) and disease-free survival (DFS)of LGG; a novel four-gene signature was constructed. The prediction model showed good predictive value over 2-, 5-, 8-, and 10-year survival probability in both the development and validation sets. The risk score effectively divided patients into high- and low- risk groups with a distinct outcome. Multivariate analysis confirmed that the risk score and status of IDH were independent prognostic predictors of LGG. Among three LGG subgroups based on the presence of molecular parameters, IDH-mutant gliomas have a favorable OS, especially if combined with 1p/19q codeletion, which further confirmed the distinct biological pattern between three LGG subgroups, and the gene signature is able to divide LGG patients with the same IDH status into high- and low- risk groups. The high-risk group possessed a higher expression of immune checkpoints and was related to the activation of immunosuppressive pathways. Finally, this study provided a convenient tool for predicting patient survival. In summary, the four prognostic genes may be therapeutic targets and prognostic predictors for LGG; this four-gene signature has good prognostic prediction ability and can effectively distinguish high- and low-risk patients. High-risk patients are associated with higher immune checkpoint expression and activation of the immunosuppressive pathway, providing help for screening immunotherapy-sensitive patients.